F3 Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma
TisVed targets high-TF-expressing IDH<sup>wt</sup> GBM, but not low-TF-expressing IDH<sup>mut</sup> glioma. This is predominately through the vedotin conjugate rather than inhibition of TF signaling. Though the effect size is modest, TisVed shows anticancer effects against IDH<sup>wt</sup> GBM. However, there could be complications related to hemostasis and hemorrhage.
Authors
- Matthew McCord (ORCID: https://orcid.org/0000-0001-7673-4463)
- Craig Horbinski (ORCID: https://orcid.org/0000-0001-8340-9992)
- Michael Drumm (ORCID: https://orcid.org/0000-0001-9696-3984)
- Thomas Sears (ORCID: https://orcid.org/0000-0003-3834-2439)
- Dusten Unruh (ORCID: https://orcid.org/0000-0003-1027-1982)
- Wenxia Wang (ORCID: https://orcid.org/0000-0003-4681-8783)
Institutions
- Northwestern University (US)
- Beckman Coulter Foundation (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-27
- DOI
- https://doi.org/10.3390/cancers17050834
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Cancer Society
- Pfizer
- National Computational Infrastructure
- National Institute of Neurological Disorders and Stroke